A binary Xpovio catalyst is set for March.
ApexOnco Front Page
Recent articles
BeOne terminates a MUC1-targeting project.
But the Japanese group is focused on biliary tract cancer rather than glioblastoma.
Astra and Daiichi bag FDA approval based on Destiny-Breast09.
On a cross-trial basis varegacestat beats Ogsiveo.
No fewer than four ADCs with this target start human testing.
The group will start a pivotal trial of samuraciclib following promising second-line results.
Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
